PMID- 11391597
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20191210
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 91
IP  - 11
DP  - 2001 Jun 1
TI  - Acquisition of secondary structural chromosomal changes in pediatric ewing 
      sarcoma is a probable prognostic factor for tumor response and clinical outcome.
PG  - 2156-64
AB  - BACKGROUND: The Ewing sarcoma (ES) group of tumors commonly have the 
      t(11;22)(q24;q12) or other rearrangements involving 22q12. In addition to these 
      consistent aberrations, both numeric and structural aberrations have been 
      reported: namely gains of chromosomes 8 and 12, the unbalanced translocation 
      t(1;16), and deletions at the short arm of chromosome 1. METHODS: To evaluate the 
      frequency and to study the prognostic implications of some of these aberrations 
      in children, the authors performed a pilot study of 26 ES pediatric patients by 
      classic cytogenetics and/or interphase fluorescence in situ hybridization (FISH) 
      and compared these data with clinical parameters. RESULTS: Gains of chromosomes 8 
      and 12 were detected, by interphase FISH, in 48% (10 of 21) and 38% (6 of 16) of 
      the tumors, respectively, and this was not significant with respect to treatment 
      response. Statistical analysis revealed that the presence of additional secondary 
      structural chromosomal aberrations was associated with an unfavorable outcome (P 
      = 0.0034 as an independent prognostic value as an unfavorable marker). Presence 
      of metastasis at diagnosis also was found to be associated with poor outcome (P = 
      0.0131). Spectral karyotyping analysis was shown to facilitate the detection of 
      more complex structural chromosomal aberrations in a representative ES tumor. 
      CONCLUSIONS: It is important to determine whether additional structural 
      chromosomal aberrations are present in ES tumors because it appears that a more 
      complex karyotype with multiple chromosomal aberrations is associated with poor 
      outcome in ES.
CI  - Copyright 2001 American Cancer Society.
FAU - Zielenska, M
AU  - Zielenska M
AD  - Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Zhang, Z M
AU  - Zhang ZM
FAU - Ng, K
AU  - Ng K
FAU - Marrano, P
AU  - Marrano P
FAU - Bayani, J
AU  - Bayani J
FAU - Ramirez, O C
AU  - Ramirez OC
FAU - Sorensen, P
AU  - Sorensen P
FAU - Thorner, P
AU  - Thorner P
FAU - Greenberg, M
AU  - Greenberg M
FAU - Squire, J A
AU  - Squire JA
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adolescent
MH  - Bone Neoplasms/*genetics/pathology
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Aberrations/*genetics
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Chromosomes, Human, Pair 12/*genetics
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Karyotyping
MH  - Male
MH  - Prognosis
MH  - Sarcoma, Ewing/*genetics/pathology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2001/06/08 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/06/08 10:00
PHST- 2001/06/08 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/06/08 10:00 [entrez]
AID - 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I [pii]
AID - 10.1002/1097-0142(20010601)91:11<2156::aid-cncr1244>3.0.co;2-i [doi]
PST - ppublish
SO  - Cancer. 2001 Jun 1;91(11):2156-64. doi: 
      10.1002/1097-0142(20010601)91:11<2156::aid-cncr1244>3.0.co;2-i.